The Top Line Teva’s CEO shares ‘Pivot to Growth’ progress
18 snips
Jun 27, 2025 Richard Francis, Teva's President and CEO, discusses his transformative journey at the helm. Over two and a half years, he has driven a 'Pivot to Growth' strategy, navigating challenges to achieve nine quarters of growth. Francis highlights Teva's innovative medicines like Austedo and Ajovy aimed at unmet medical needs, while also addressing the importance of expanding generics and biosimilars internationally. With a focus on modernization and a $700 million cost reduction, he shares insights into fostering long-term growth and staying committed to patient care.
AI Snips
Chapters
Transcript
Episode notes
Ambitious Growth in Innovation
- Teva expects over $5 billion in innovative drug sales by 2030 driven by portfolio growth.
- Products like Esteto, Ajovi, and Yoseti are transformational and address unmet medical needs.
Bridging Treatment Gaps
- Educate patients and caregivers through direct-to-consumer campaigns to identify symptoms early.
- Train physicians to diagnose and treat tardive dyskinesia to close the treatment gap.
Comprehensive Schizophrenia Solutions
- Combining Yoseti and Olanzapine long-acting injectables could cover all schizophrenia patients effectively.
- Olanzapine’s long-acting form addresses a major unmet need with potential sales of $1.5–2 billion.